 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12345678910» |
- Imdelltra (tarlatamab-dlle) / Amgen
ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer and ECOG PS 2 () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5833;
- Imdelltra (tarlatamab-dlle) / Amgen
Proactive Steroid Use Reduces Toxicity While Preserving Clinical Outcomes in Tarlatamab-Treated SCLC: Real-World Evidence from a Community Cancer Center () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5824;
- Imdelltra (tarlatamab-dlle) / Amgen
Single-centre cohort of real-world tarlatamab delivery in DLL3-expressing high-grade neuroendocrine and small cell carcinomas. () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5823;
- Imdelltra (tarlatamab-dlle) / Amgen
External Validity of Tarlatamab in Relapsed SCLC: The CNS Paradox and Safety Shift in Trial-Ineligible Populations () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5817;
- Imdelltra (tarlatamab-dlle) / Amgen
A multicenter retrospective study of real-world safety and efficacy of tarlatamab in pulmonary large cell neuroendocrine carcinomas (LCNEC) (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3540;
- Imdelltra (tarlatamab-dlle) / Amgen
Ablative Radiotherapy Meets T-Cell Engagement: SABR During Tarlatamab in Oligoprogressive ES-SCLC (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3409;
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world safety of outpatient, inpatient, and hybrid tarlatamab administration in small cell lung cancer (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3406;
- Imdelltra (tarlatamab-dlle) / Amgen
Real-World Effectiveness and Safety of Tarlatamab in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer from the Canadian Small Cell Lung Cancer Database (CASCADE) (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3404;
- Imdelltra (tarlatamab-dlle) / Amgen
Cytokine Release Syndrome in Patients Receiving Tarlatamab for Extensive-Stage Small Cell Lung Cancer: A Real-World Analysis (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3402;
- Imdelltra (tarlatamab-dlle) / Amgen
Prolonged Clinical Benefit Through Local Ablative Therapy and Continuation of Tarlatamab Beyond Oligoprogression in Extensive-Stage Small Cell Lung Cancer (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3399;
- Imdelltra (tarlatamab-dlle) / Amgen
Outcomes of elderly patients with SCLC treated with tarlatamab: A retrospective multicenter study from the ONWARD-SCLC consortium. (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3388;
- Imdelltra (tarlatamab-dlle) / Amgen
Sustained Survival With Extended Follow-Up of Tarlatamab Plus Anti-PD-L1 as First-Line Maintenance (1LM) After Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC): DeLLphi-303 Phase 1b Study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3375;
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world safety and efficacy of tarlatamab in extrapulmonary neuroendocrine carcinomas (EP-NEC): A multicenter retrospective study from the ONWARD-SCLC consortium. (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2734;
- Imdelltra (tarlatamab-dlle) / Amgen
Tarlatamab in Previously Treated SCLC: Extended Follow-up of Overall Survival from the Phase 3 DeLLphi-304 Trial (Burgos Auditorium - Hall 3) - Jul 17, 2026 - Abstract #ESMO2026ESMO_1540;
- |||||| Imdelltra (tarlatamab-dlle) / Amgen
Enrollment open: DeLLphi-312: A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov) - Jul 10, 2026
P3, N=330, Recruiting, Sponsor: Amgen
-> Recruiting
- | Imdelltra (tarlatamab-dlle) / Amgen
Trial completion date: DeLLphi-307: Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (clinicaltrials.gov) - Jul 9, 2026
P2, N=32, Active, not recruiting, Sponsor: Amgen
-> Recruiting Trial completion date: Jan 2027 --> Sep 2027
- || Imdelltra (tarlatamab-dlle) / Amgen
Enrollment change: DeLLphi-310: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - May 20, 2026
P1, N=29, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jan 2027 --> Sep 2027 N=200 --> 29
- | Imdelltra (tarlatamab-dlle) / Amgen
Journal: Discrepant Intracranial and Extracranial Responses to Tarlatamab in Relapsed Small-Cell Lung Cancer With Untreated Brain Metastases: A Case Report. (Pubmed Central) - May 13, 2026
Possible explanations include limited drug penetration across an intact blood-brain barrier and biological heterogeneity between metastatic sites. Careful neurological assessment and early brain imaging should be considered when using tarlatamab in patients with untreated brain metastases.
- | Review, Journal, PD(L)-1 Biomarker, IO biomarker: Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations. (Pubmed Central) - May 7, 2026
TCEs have achieved major success in hematologic malignancies and now show promise in selected solid tumors, with the approvals of tebentafusp and tarlatamab in uveal melanoma and small cell lung cancer, respectively, establishing proof of concept that durable benefit is possible...ADC-checkpoint inhibitor combinations are similarly reshaping solid tumor therapy, most notably in urothelial carcinoma, where enfortumab vedotin plus pembrolizumab has demonstrated substantial survival gains...Emerging drug engineering approaches and biomarker-driven patient selection aim to improve efficacy while limiting toxicity. Together, these advances support a new era of precision immuno-oncology, but broader success will require improved biomarkers, rational combinations, and an understanding of resistance mechanisms.
- | Imdelltra (tarlatamab-dlle) / Amgen
Journal, HEOR, Cost-effectiveness: Cost-Effectiveness of Tarlatamab in the Second-Line Treatment of Refractory Small Cell Lung Cancer From a US Perspective. (Pubmed Central) - May 1, 2026
Sensitivity and scenario analyses confirmed the robustness of the cost-effectiveness results. At WTP thresholds of $150?000/QALY and $200?000/QALY, tarlatamab was not considered a cost-effective option at the current price compared with chemotherapy for the treatment of recurrent ESCLC from the US payer perspective.
- || Imdelltra (tarlatamab-dlle) / Amgen
Enrollment change: Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (clinicaltrials.gov) - Apr 30, 2026
P1, N=220, Recruiting, Sponsor: Amgen
At WTP thresholds of $150?000/QALY and $200?000/QALY, tarlatamab was not considered a cost-effective option at the current price compared with chemotherapy for the treatment of recurrent ESCLC from the US payer perspective. N=86 --> 220
- | Imdelltra (tarlatamab-dlle) / Amgen
Trial initiation date: START-lung: A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 (clinicaltrials.gov) - Apr 30, 2026
P2, N=48, Recruiting, Sponsor: ETOP IBCSG Partners Foundation
- ||||| Imdelltra (tarlatamab-dlle) / Amgen
Enrollment closed: DeLLphi-306: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov) - Apr 29, 2026
P3, N=404, Active, not recruiting, Sponsor: Amgen
N=86 --> 220 Recruiting --> Active, not recruiting
- | Review, Journal, PD(L)-1 Biomarker, IO biomarker: Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance. (Pubmed Central) - Apr 29, 2026
Platinum-etoposide has long been the standard first-line therapy, and the recent incorporation of immune checkpoint inhibitors (ICIs) such as atezolizumab (IMpower133) and durvalumab (CASPIAN, ADRIATIC) has modestly improved survival, including a new role for durvalumab as a consolidation therapy in limited-stage SCLC...Emerging approaches include DLL3-directed bispecific T-cell engagers (BiTEs), such as tarlatamab and obrixtamig, which have shown promising efficacy in relapsed disease, and next-generation antibody-drug conjugates (ADCs) targeting DLL3, B7-H3, TROP2, and SEZ6...Future therapeutic efforts will require biomarker-driven strategies that incorporate molecular subtyping (ASCL1, NEUROD1, POU2F3, and YAP1) and immune profiling to facilitate precise treatment selection. Combining ICIs, BiTEs, ADCs, and cellular or radioligand therapies in rational, evidence-based regimens represents a promising avenue to improve outcomes in this historically intractable disease.
- | Imdelltra (tarlatamab-dlle) / Amgen, Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer (clinicaltrials.gov) - Apr 27, 2026
P1/2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Combining ICIs, BiTEs, ADCs, and cellular or radioligand therapies in rational, evidence-based regimens represents a promising avenue to improve outcomes in this historically intractable disease. N=120 --> 0 | Trial completion date: Dec 2030 --> Apr 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2029 --> Apr 2026
- ||| Imdelltra (tarlatamab-dlle) / Amgen
Enrollment change: START-lung: A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 (clinicaltrials.gov) - Apr 26, 2026
P2, N=40, Recruiting, Sponsor: ETOP IBCSG Partners Foundation
N=120 --> 0 | Trial completion date: Dec 2030 --> Apr 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2029 --> Apr 2026 N=30 --> 40
- || Imdelltra (tarlatamab-dlle) / Amgen
Enrollment closed: DeLLphi-310: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Apr 23, 2026
P1, N=200, Active, not recruiting, Sponsor: Amgen
N=30 --> 40 Suspended --> Active, not recruiting
- ||| Imdelltra (tarlatamab-dlle) / Amgen
Enrollment open, Enrollment change, Trial initiation date: START-lung: A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 (clinicaltrials.gov) - Apr 21, 2026
P2, N=48, Recruiting, Sponsor: ETOP IBCSG Partners Foundation
Suspended --> Active, not recruiting Not yet recruiting --> Recruiting | N=30 --> 48
- Imdelltra (tarlatamab-dlle) / Amgen
DLL3-targeted therapy with tarlatamab in small cell lung cancer across lines of therapy: A systematic review of prospective and randomized clinical trials. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_7639;
Not yet recruiting --> Recruiting | N=30 --> 48 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world experience with tarlatamab in extensive-stage small cell lung cancer at an academic center in Mississippi. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_7490;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world efficacy and safety of tarlatamab in extensive-stage small-cell lung cancer: A single-center retrospective study at university of Missouri. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_7272;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world outcomes of tarlatamab across small cell carcinoma subtypes, including transformed and non-lung primary. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_7070;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world safety of tarlatamab in patients receiving recent or concurrent CNS radiation. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6853;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Do mental health disorders modify cytokine release syndrome risk in immune effector cell therapy? Full-cohort analysis with tarlatamab validation. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6851;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Evaluation of atezolizumab, durvalumab, lurbinectedin, and tarlatamab in high-grade extrapulmonary neuroendocrine carcinoma: A multicenter retrospective comparative analysis. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6741;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world survival and safety outcomes of tarlatamab in patients with extensive stage small cell lung cancer. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6245;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world outcomes associated with tarlatamab for extensive-stage small cell lung cancer (ES-SCLC) in the Veterans Health Administration (VA). () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6209;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world efficacy and safety of tarlatamab in small cell lung cancer and extrapulmonary neuroendocrine carcinoma. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6186;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world efficacy and safety of tarlatamab in small cell lung cancer (SCLC) and extrapulmonary small cell carcinoma (EPSCC): A single-center experience. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6185;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world analysis of CRS and ICANS following tarlatamab and its association with survival in patients with SCLC. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6161;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Performance status and tarlatamab outcomes in a large, multi-institution real-world database of 2L+ ES-SCLC. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6023;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Outcomes of infectious workup and antibiotic use during tarlatamab initiation in patients with advanced neuroendocrine carcinomas. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_5960;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Cost of cytokine release syndrome in patients treated with tarlatamab for extensive-stage small cell lung cancer based on first-line treatment. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_5098;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
A retrospective analysis of tarlatamab outcomes and safety in a global multicenter electronic health record network (TriNetX) database. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4635;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis. (Hall D1) - Apr 21, 2026 - Abstract #ASCO2026ASCO_3664;
P3
Funded by Amgen Inc. Clinical Trial Registration Number: NCT05740566 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Tarlatamab in small cell lung cancer with brain metastases: A real-world experience. (Hall A - Posters and Exhibits; Poster Bd #: 582) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2524;
Clinical Trial Registration Number: NCT05740566 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma
Prophylactic tocilizumab to mitigate cytokine release syndrome in patients receiving tarlatamab: A single?center exploratory experience informed by bispecific antibody safety data. (Hall A - Posters and Exhibits; Poster Bd #: 556) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2511;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Predictive markers of response and toxicity to tarlatamab in patients with extensive stage small cell lung cancer (ES-SCLC): A multi-institutional real-world analysis. (Hall A - Posters and Exhibits; Poster Bd #: 571) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2507;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Noninvasive imaging biomarkers for survival risk stratification with tarlatamab in ES-SCLC. (Hall A - Posters and Exhibits; Poster Bd #: 494) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2501;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by National Cancer Institute, National Cancer Institute, National Cancer Institute, National Cancer Institute, National Cancer Institute, Lung Cancer research Program Career Development Award, Lung Cancer Research Program The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imdelltra (tarlatamab-dlle) / Amgen
Impact of DLL3 expression and tumor subtype on response to tarlatamab. (Hall A - Posters and Exhibits; Poster Bd #: 561) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2487;
Funded by National Cancer Institute, National Cancer Institute, National Cancer Institute, National Cancer Institute, National Cancer Institute, Lung Cancer research Program Career Development Award, Lung Cancer Research Program The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.